타이샤 유전자 치료제즈(TSHA) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

Q: What kind of company is 타이샤 유전자 치료제즈(TSHA)?

타이샤 유전자 치료제즈(TSHA) belongs to the Healthcare sector and operates in the Biotechnology industry.

Q: What is the market cap of TSHA?

The market cap of TSHA is approximately $1.8B, ranking 2,210 within its sector.

Q: What is the 52-week high and low for TSHA?

TSHA has recorded a 52-week high of $7.30 and a low of $2.53.

TSHA

Taysha Gene Therapies Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$5.54

+0.02 ▲ +0.36%

🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)

$5.59

+0.05 ▲ +0.90%

타이샤 유전자 치료제즈(TSHA) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$1.8B

스몰캡

P/E

배당수익률

없음

52주 위치

63%

저점 +119% · 고점 -24%

애널리스트

적극 매수

Fundamental health

vs. 성장주 소형주· based on 3 axes

수익성

산출 불가 (적자)

성장

Top 64%

밸류에이션

Top 14%

재무 안정

Top 32%

Index ⓘ	RUT	P/E ⓘ	-	EPS (ttm) ⓘ	-0.4	Insider Own ⓘ	17.11%	Shs Outstand ⓘ	287.3M	Perf Week ⓘ	-0.72%
Market Cap ⓘ	1.77B	Forward P/E ⓘ	-	EPS next Y ⓘ	1.25%	Insider Trans ⓘ	-1.44%	Shs Float ⓘ	265.1M	Perf Month ⓘ	-10.79%
Enterprise Value ⓘ	1.56B	PEG ⓘ	-	EPS next Q ⓘ	-0.11	Inst Own ⓘ	80.74%	Short Float ⓘ	17.08%	Perf Quarter ⓘ	-13.44%
Income ⓘ	-0.13B	P/S ⓘ	237.22	EPS this Y ⓘ	-36.43%	Inst Trans ⓘ	-2.27%	Short Ratio ⓘ	15.01	Perf Half Y ⓘ	18.88%
Sales ⓘ	0.01B	P/B ⓘ	7.51	EPS next 5Y ⓘ	11.94%	ROA ⓘ	-59.21%	Short Interest ⓘ	45.29M	Perf YTD ⓘ	0.73%
Book/sh ⓘ	0.74	P/C ⓘ	6.4	EPS past 3/5Y ⓘ	55.14% 36.86%	ROE ⓘ	-97.28%	52W High ⓘ	-24.11% ($7.30)	Perf Year ⓘ	109.06%
Cash/sh ⓘ	0.87	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	57.49% -	ROIC ⓘ	-46.61%	52W Low ⓘ	119.41% ($2.53)	Perf 3Y ⓘ	784.28%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	-11.04%	Gross Margin ⓘ	84.51%	Volatility(W/M) ⓘ	6.29% 7.65%	Perf 5Y ⓘ	-68.93%
Dividend TTM ⓘ	-	EV/Sales ⓘ	209.35	Sales Y/Y TTM ⓘ	3.42%	Oper. Margin ⓘ	-1774.37%	ATR (14) ⓘ	0.43	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	14.03	EPS Q/Q ⓘ	-44.81%	Profit Margin ⓘ	-1738.4%	RSI (14) ⓘ	42.17	Recom ⓘ	1.08
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	14.03	Sales Q/Q ⓘ	-100%	SMA20 ⓘ	-9.18% ($6.1)	Beta ⓘ	1.22	Target Price ⓘ	$13.15
Payout ⓘ	-	Debt/Eq ⓘ	0.32	Earnings ⓘ	2026/5/6	SMA50 ⓘ	-7.03% ($5.96)	Rel Volume ⓘ	0.78	Prev Close ⓘ	$5.52
Employees ⓘ	99	LT Debt/Eq ⓘ	0.31	EPS/Sales Surpr. ⓘ	-24.1% -100%	SMA200 ⓘ	5.75% ($5.24)	Avg Volume(3M) ⓘ	3.02M	Price ⓘ	$5.54
IPO ⓘ	2020/9/24	Option/Short ⓘ	Yes/Yes			Trades ⓘ	13202	Volume ⓘ	2,365,141	Change ⓘ	0.36%

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12*

25.3

25.6

25.9

25.12*

26.3

Revenue Net income 최근 분기: 매출 $0M (YoY -100%) · 순이익 $-42M (YoY -97%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Taysha Gene Therapies Inc (TSHA) Investment Analysis

What kind of company is Taysha Gene Therapies Inc?

타이샤 유전자 치료제즈(TSHA) 성장주

Healthcare · Biotechnology

Healthcare Stocks

A US clinical-stage biotech company developing gene therapies for central nervous system (CNS) genetic disorders. It uses viral vector-based gene therapy technology to develop treatments that target monogenic CNS diseases and holds a leading candidate for rare neurogenetic disorders. The company enters the underserved CNS disease market through a differentiated gene therapy approach.

Learn more about Taysha Gene Therapies Inc →

Market Cap

$1.8B

Approx. KRW 2.4 trillion

⚖️ 1% of Samsung Electronics

Market Cap Rank2210

Employees99people

IPO2020/09/24

Current Price$5.54 ≈ 7,590원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 6일 (수) · 장 시작 전 EPS -24.1% 매출 -100.0%

🔔 Earnings release 2026년 3월 19일 (목) · 장 시작 전 EPS +16.3% 매출 +144.5%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-1774.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-1738.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

84.5%

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology 소형주 Median 84.9% · Bottom 50%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-97.3%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-59.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-46.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.32

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

14.03

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

14.03

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$13.15

현재가 대비 +137.4%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

+1.3%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+11.9%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

+5.7%

평균 서프라이즈

2026.05.06

하회

실적 $-0.11 · 예상 $-0.10 -14.0%

2026.03.19

상회

실적 $-0.07 · 예상 $-0.10 +25.3%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow

Historical growth is expected to lose momentum

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

-36.4%

매우 부진

My positionBottom 5%

Low range Average High range

성장주 소형주 Median 16.2% · Bottom tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+1.3%

부진

My positionBottom 25%

Low range Average High range

성장주 소형주 Median 17.5% · Bottom 11%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+11.9%

부진

My positionBottom 25%

Low range Average High range

성장주 소형주 Median 18.9% · Bottom 16%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+55.1%

우수

My positionTop 25%

Low range Average High range

성장주 소형주 Median 8.7% · Top 12%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+36.9%

우수

My positionTop 5%

Low range Average High range

성장주 소형주 Median 2.9% · Top tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-100.0%

매우 부진

My positionBottom 5%

Low range Average High range

성장주 소형주 Median 7.0% · Bottom tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -137%p below the market

TSHA -68.9% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-137.3%p

Significantly behind the market

vs Health Care (XLV)

-93.4%p

Significantly behind the sector average

1-year basis

vs S&P 500

+93.0%p

well ahead of the market

vs Health Care (XLV)

+89.3%p

well ahead of the sector average

Rank among peers

5-year return Lower-Mid (lower 40%) Based on 123 peers

1-year return Upper-Mid (34%) Based on 154 peers

Current position within 52-week range

Low (-119.4%p) High (-24.1%p)

Current price is 119.4% above the 52-week low and 24.1% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-25.8%

Annualized volatility

74.2%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $5.54 below the midline ($6.10). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴

Current diagnosis · 2026-07-27

Bearish momentum holding

MACD -0.154 < Signal -0.077 in negative zone + Hist negative (-0.076). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-27

Bearish zone

RSI 42.2 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 17.7.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry

Pricey on Vs. Assets·Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Pricey

🧾 Vs. Sales Pricey

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

7.51x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology 소형주 median 3.34x · Bottom 18% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

237.22x

✓ Very pricey

My positionBottom 25%

Low range Average High range

Biotechnology 소형주 median 14.61x · Bottom 10% — expensive within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$13.15 vs. current price +137.4%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership backdrop is unfavorable

Insider modest net selling -1.4% · Institutional net selling -2.3% · Short interest elevated 17.1% · Short interest fell -5.1%p over the last 90 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-1.4%

Insiders net selling

🏦 Institutions (funds & investors)

-2.3%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 80.7%

Institution-led, stable structure

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 17.1%

Founder/management large holders (strong skin-in-the-game)

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 2.2%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

17.1%

Somewhat high

Healthcare 소형주 Median 11.2%

Past 90 days 📉 -5.1%p decrease

Short interest days to cover

15.0 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 287.3M주

Float (tradable shares) 265.1M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding TSHA

ETFs with the highest weightings · 10 total shown

IBRN

iShares Neuroscience and Healthcare ETF

1.53%

$6M

BBC

Virtus Biotech Clinical Trials ETF

0.82%

$47M

SBIO

ALPS Medical Breakthroughs ETF

0.80%

$202M

SGRW

Harbor Active Small Cap Growth ETF

0.46%

$5M

LABU

Direxion Daily S&P Biotech Bull 3X ETF

0.40%

$546M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
TSHA This Stock	$1.8B	-	7.5 ▼	-97.28% ▼	-	+0.4%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 타이샤 유전자 치료제즈(TSHA)?

타이샤 유전자 치료제즈(TSHA) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of TSHA?

The market cap of TSHA is approximately $1.8B, ranking 2,210 within its sector.

What is the 52-week high and low for TSHA?

TSHA has recorded a 52-week high of $7.30 and a low of $2.53.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.